SANDRA MATTHEWS: Open Payments
NPI 1982909453 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$886 in 48 payments from 13 companies in 2025. Trend: 2023 $799 · 2024 $1,047 · 2025 $886
Food & beverage: $886
| Company | Payments | Amount |
|---|---|---|
| Genentech USA, Inc. | 7 | $174 |
| Amgen Inc. | 10 | $135 |
| Regeneron Healthcare Solutions, Inc. | 7 | $133 |
| Novartis Pharmaceuticals Corporation | 5 | $114 |
| Astellas Pharma US Inc | 4 | $79 |
| Lilly USA, LLC | 4 | $66 |
| ABBVIE INC. | 3 | $50 |
| Novo Nordisk Inc | 2 | $35 |
| AstraZeneca Pharmaceuticals LP | 2 | $29 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $25 |
Products named: Xolair, DUPIXENT, Veozah, EVENITY, OTEZLA, MOUNJARO, VRAYLAR, FARXIGA.
Industry payments across MS — which companies pay providers there.
